PDE5 inhibitors for LUTS

Samdeep K Mouli, K. T. McVary*

*Corresponding author for this work

Research output: Contribution to journalReview article

22 Scopus citations

Abstract

To review the current literature regarding the relationship between lower urinary tract symptoms (LUTS) and erectile dysfunction (ED), and the role of phosphodiesterase-5 (PDE5) inhibitors for the treatment of LUTS. Review of recently published (1990-2009) data regarding epidemiologic and pathophysiologic mechanisms are involved in LUTS-ED, focusing on PDE5 inhibitors particularly evidenced from level 1 clinical trials. Search terms included phosphodiesterase inhibitors, nitric oxide, autonomic hyperactivity, Rho-kinase, atherosclerosis, LUTS, benign prostatic hypertrophy, and ED. Results of several epidemiologic studies show a possible causal relationship between LUTS and ED. Four possible mechanisms have been proposed to explain this association. Multiple large clinical trials have shown a benefit in LUTS after PDE5-inhibitors treatment. PDE5 inhibitors show promise as a future treatment for LUTS, either in conjunction with existing therapies or as a primary treatment.

Original languageEnglish (US)
Pages (from-to)316-324
Number of pages9
JournalProstate Cancer and Prostatic Diseases
Volume12
Issue number4
DOIs
StatePublished - Aug 19 2009

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Cancer Research

Fingerprint Dive into the research topics of 'PDE5 inhibitors for LUTS'. Together they form a unique fingerprint.

Cite this